Cariprazine (Mapi Pharma)

N/A

Report date: 2026/04/08 15:42:04

Base Information

Drug NameCariprazine (Mapi Pharma)
Drug Alias NameCariprazine Once Monthly Injection (Mapi Pharma)2nd generation to Vraylar (Mapi Pharma)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSerotonin 2a (5-HT2a) receptor antagonistsDopamine D2 receptor partial agonistsDopamine D3 receptor partial agonists +[6] 
TargetsSerotonin 2a (5-HT2a) receptorDopamine D2 receptorDopamine D3 receptor +[6] 
Therapy Area/IndicationsSchizophrenia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryIsrael
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesMapi Pharma Ltd
China Registration ClassN/A

Develop Information

Active CompaniesMapi Pharma Ltd
Inactive CompaniesN/A
Active IndicationsSchizophrenia
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A